AMRX Amneal Pharmaceuticals, Inc.

8-K Current Report

Filed: February 27, 2026

Health Care

Pharmaceutical Preparations

Amneal Pharmaceuticals, Inc. (AMRX) 8-K current report filed with SEC EDGAR on February 27, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Q4 and full-year 2025 earnings released Feb 27, 2026; results cover period ended December 31, 2025
• Full financials in Exhibit 99.1 press release — key figures not disclosed in this filing item

Item 7.01 · Regulation FD Disclosure

• Amneal hosting earnings call Feb 27, 2026 at 8:30am ET to discuss quarterly/annual results
• Webcast accessible at investors.amneal.com; dial-in (833) 470-1428, access code 937407

+1 more insights

Get deeper insights on Amneal Pharmaceuticals, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.